Phase 4 Glaucoma Trial, Recruiting NCT07396441 Sponsor: Universiti Sains Malaysia Condition: Glaucoma
Back to Glaucoma

Phase 4 Glaucoma Trial, Recruiting

NCT07396441
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who were diagnosed with Juvenile Open-Angle Glaucoma (a type of eye condition affecting younger people) between the ages of 15 and 40 years old at the time of diagnosis
  • People who have been following their prescribed glaucoma treatment and have reached their target eye pressure levels

Who may not be able to join:

  • People who have a known allergy to honey or products that contain honey
  • People whose eye scan (OCT) quality score is below 6 out of 10
  • People who have other retinal (back of the eye) diseases or other conditions affecting the optic nerve
  • People who have a condition that causes the nervous system to break down over time (confirm with trial site)
  • People who have conditions such as diabetes or autoimmune diseases (where the immune system attacks the body)
  • People who have used honey-based products in the three months before joining the trial
  • People who consume honey-based products at any point during the three months of the study (this is tracked through a diary and by returning used product sachets at follow-up visits)
  • People who have taken antioxidant supplements, traditional medicines, or herbal products in the three months before joining the trial
  • People who are using steroid eye drops, taking steroids by mouth or injection, or taking anti-inflammatory medicines
  • People who have or have had sepsis (a serious, life-threatening response to infection)
  • People whose rate of following the study requirements falls below 75%

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Azhany Yaakub, MD, MMed, PhD, Universiti Sains Malaysia

Phone: +60177712935

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Universiti Sains Malaysia
Registry
ClinicalTrials.gov
Start date
15 January 2026
Est. completion
15 May 2026

Where this trial is recruiting

🇲🇾 Malaysia

Primary endpoints

Change in the level of serum Interleukin-6 level before and after consumption of stingless bee honey for 3 months among patients with juvenile open angle glaucoma; serum Interleukin 6 level

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov